Jun. 11 at 12:18 PM
$VIR
MS to 27$
The Fly
Morgan Stanley raised the firm’s price target on Vir Biotechnology (VIR) to
$27 from
$23 and keeps an Overweight rating on the shares. Hepatitis delta virus remains underdiagnosed and recent U.S. approval of bulevirtide sets the stage for market expansion, says the analyst, who believes the next wave of therapies from Vir and Mirum Pharmaceuticals (MIRM) represent notable improvements and are “best positioned to benefit in this currently underappreciated market.
